Synthesis and preparation methods of SHP2 and CDK4 / 6 dual target inhibitor compounds and their uses
Novel dual-targeted SHP2 and CDK4/6 inhibitors, synthesized through pharmacophore fusion, address the issues of low efficacy and resistance by maintaining activity against both targets and enhancing therapeutic outcomes.
Patent Information
- Application Number
- JP2024525107
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-07-21
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
SHP2 and CDK4/6 inhibitors exhibit low clinical therapeutic efficacy and are prone to drug resistance when used over a long period, necessitating the development of novel dual-targeted compounds to overcome these limitations.
The synthesis of dual-targeted inhibitors comprising SHP2 and CDK4/6, represented by specific chemical compounds and their pharmaceutically acceptable forms, through pharmacophore fusion and rational drug design, to enhance efficacy and combat drug resistance.
The novel dual-targeted inhibitors demonstrate improved drug resistance and non-sufficiency by maintaining activity against both targets, with compounds showing significant inhibitory effects in vitro and cell cycle arrest, particularly compound 14 exhibiting excellent G0/G1 phase stopping activity.
Smart Images

Figure 2024541018000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicinal chemistry, specifically to the synthesis of dual-target inhibitors including SHP2 and CDK4 / 6, and the preparation method thereof and the use thereof. [Background technology]
[0002] SHP2 is a non-receptor protein tyrosine phosphatase that is widely distributed in the body and has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. These two SH2 domains control the subcellular localization and functional regulation of SHP2. As a downstream signaling molecule of growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast factor (FGF), interleukin-3 (IL-3), leukemia inhibitory factor (LIF), and α-interferon (INF-α), SHP2 is involved in multiple signaling pathways such as the RAS / MARK pathway, the PI3K / AKT pathway, the JAK / STAT pathway, and the JNK pathway. Studies have shown that mutations or overactivation of SHP2 causes Noonan syndrome, juvenile myelomonocytic leukemia, myelodysplastic syndromes, B-cell acute lymphoblastic leukemia, and solid tumors (lung cancer, colon cancer, neuroblastoma, melanoma, and liver cancer).
[0003] CDK is a type of serine / threonine protein kinase. Among them, CDK4 / 6 is a major regulator of the cell cycle, controlling the changes in each phase of the cell cycle, and is one of the important targets of antitumor drugs. CDK4 / 6 inhibitors can produce antitumor activity by inhibiting the transition from G1 to S phase of the tumor cell cycle, activating antitumor immune responses, affecting the tumor microenvironment, etc., and have excellent clinical efficacy against certain types of tumors. However, long-term treatment with CDK4 / 6 inhibitors can easily cause tumor drug resistance and lose the efficacy of the inhibitors.
[0004] Research has shown that the combination of SHP2 inhibitors and CDK4 / 6 inhibitors has a strong synergistic effect. This combination therapy is currently in phase I clinical trials and is being used to treat malignant tumors such as head and neck cancer, non-small cell lung cancer, and colon cancer.
[0005] The present invention provides a basis for preparing novel SHP2 and CDK4 / 6 dual-target inhibitors through pharmacophore fusion and rational drug design, and solving the problem of drug resistance of kinases and phosphatases. Summary of the Invention [Problem to be solved by the invention]
[0006] One of the technical problems that the present invention aims to solve is the problem that SHP2 inhibitors and CDK4 / 6 inhibitors have low clinical therapeutic effects and are prone to drug resistance when used for a long time. Therefore, a novel dual target inhibitor compound including SHP2 and CDK4 / 6 is provided, which enables further drug development. [Means for solving the problem]
[0007] The solutions to the above technical problems are as follows: Compounds of general formula I, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof: [ka] (Ring A is C3-C6 cycloalkyl, C6-C 10 Aromatic ring, C6~C 10 cycloalkyl, aromatic ring, heteroaromatic ring, heterocyclic ring, spiro ring, bridged ring, fused ring, wherein the cycloalkyl, aromatic ring, heteroaromatic ring, heterocyclic ring, spiro ring, bridged ring, fused ring are selected from N, O, and S(O) mwherein m is selected from 0, 1, and 2, and wherein said cycloalkyl, aromatic ring, heteroaromatic ring, carbocycle, monoheterocycle, spirocycle, bridged ring, fused ring may optionally be substituted by one or more substituents; Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1, and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 1 is a chemical bond, NR a , C1-C2 carbon chain, O, S(O) m where m is selected from 0, 1, and 2; L 2 is a chemical bond, NR a , C1-C2 carbon chain, O, S(O) m where m is selected from 0, 1, and 2; Y 1 is N or CR 3 where R 3 is selected from hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C6 cycloalkyl; Y 2 is N or CR 4 where R 4 is selected from hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, or C3-C6 cycloalkyl; R 1 and R 2are respectively hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 1 and R 2 form a 3- to 12-membered monoheterocycle or polyheterocycle together with the carbon atom to which they are attached, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: [ka] where W is absent or CR 6 R 7 , O, N.R. b , S(O) m where m is selected from 0, 1, and 2; The C ring is absent or is a C3-C7 membered monocyclic ring or a C5-C 12 is selected from polycyclic rings, R a and R b are each independently a hydrogen atom, a deuterium atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C6-C 10 Aryl, C6-C 10 heteroaryl; R 4 , R 5 , R 6 , and R 7are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, a C1 to C6 alkyl group, a C3 to C6 cycloalkyl group, a C6 to C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C3-C together with the carbon atoms to which they are attached. 12 3-4.)
[0008] Compounds represented by general formula II, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs, or prodrugs thereof: [ka] (Ring A is C3-C6 cycloalkyl, C6-C 10 Aromatic ring, C6~C 10 cycloalkyl, aromatic ring, heteroaromatic ring, heterocyclic ring, spiro ring, bridged ring, fused ring, wherein the cycloalkyl, aromatic ring, heteroaromatic ring, heterocyclic ring, spiro ring, bridged ring, fused ring are selected from N, O, and S(O) m wherein m is selected from 0, 1, and 2, and wherein said cycloalkyl, aromatic ring, heteroaromatic ring, carbocycle, monoheterocycle, spirocycle, bridged ring, fused ring may optionally be substituted by one or more substituents; Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1, and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 1 is a chemical bond, NRa , C1-C2 carbon chain, O, S(O) m where m is selected from 0, 1, and 2; L 2 is a chemical bond, NR a , C1-C2 carbon chain, O, S(O) m where m is selected from 0, 1, and 2; R 1 and R 2 are hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C1-C6 alkyl, C6-C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 1 and R 2 form a 3- to 12-membered monoheterocycle or polyheterocycle together with the carbon atom to which they are attached, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: [ka] where W is absent or CR 6 R 7 , O, N.R. b , S(O) m where m is selected from 0, 1, and 2; The C ring is absent or is a C3-C7 membered monocyclic ring or a C5-C 12 is selected from polycyclic rings, R a and R bare each independently a hydrogen atom, a deuterium atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C6-C 10 Aryl, C6-C 10 heteroaryl; R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, a C1 to C6 alkyl group, a C3 to C6 cycloalkyl group, a C6 to C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C3-C together with the carbon atoms to which they are attached. 12 3-4.)
[0009] Compounds represented by general formula III, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. [ka] (A ring is hydrogen, [ka] is selected from Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1, and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 2 is a chemical bond, NR a , C1-C2 carbon chain, O, S(O)m where m is selected from 0, 1, and 2; R 1 and R 2 are respectively hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 1 and R 2 form a 3- to 12-membered monoheterocycle or polyheterocycle together with the carbon atom to which they are attached, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: [ka] where W is absent or CR 6 R 7 , O, N.R. b , S(O) m where m is selected from 0, 1, and 2; The C ring is absent or is a C3-C7 membered monocyclic ring or a C5-C 12 is selected from polycyclic rings, R a and R b are each independently a hydrogen atom, a deuterium atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C6-C 10 Aryl, C6-C 10 heteroaryl; R 4 , R 5 , R 6, and R 7 are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, a C1 to C6 alkyl group, a C3 to C6 cycloalkyl group, a C6 to C 10 Aryl, C6-C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C3-C together with the carbon atoms to which they are attached. 12 3-4.)
[0010] A pharmaceutical composition comprising a compound I-III and a pharma- ceutical acceptable excipient.
[0011] A pharmaceutical composition which is formulated into a tablet, capsule, injection, or lyophilized powder.
[0012] Use of said aryl spirocyclic compounds, said pharmaceutical compositions in the preparation of antineoplastic drugs, prodrugs of antineoplastic drugs or intermediates of antineoplastic drugs.
[0013] Design scheme: [ka]
[0014] In designing dual-target drugs, the pharmacophore fusion design method can often avoid problems such as high molecular weight and poor metabolism. In designing SHP2 / CDK4 dual-target inhibitors, we observed that both of them have pyridine rings and the modifications are at the edge of the solvent region, so we innovatively integrated their pharmacophores and linking groups. Since this fusion-type dual-target inhibitor is difficult to balance the activity between the two targets, we simply investigated the effects of different pharmacophores and linking groups on the inhibitory activity, and obtained compounds 1-26.
[0015] SAR analysis revealed that compounds with two pharmacophores linked at the para position via a pyridine ring could maintain CDK4 activity but reduce SHP2 activity. Compounds with two pharmacophores linked at the meta position via a pyridine ring could maintain SHP2 activity but reduce CDK activity. The overall effect of Abemaciclib's pharmacophore is superior to that of Ribociclib. In summary, we investigated the SAR of SHP2 / CDK4 dual target inhibitors by synthesizing 26 compounds and obtained several compounds with dual target inhibitory activity. Effect of the Invention
[0016] Beneficial effects 1. The present invention solves the traditional problems of drug resistance and insufficient efficacy of SHP2 inhibitors and CDK4 / 6 inhibitors by preparing a novel SHP2 and CDK4 / 6 dual-target inhibitor through pharmacophore fusion and rational drug design. 2. In vitro enzyme activity and antiproliferative activity tests showed that compounds 10, 14, 19, 23, 25 and 26 exhibited good dual target inhibitory activity, and in cell cycle experiments, compound 14 showed excellent G0 / G1 arresting activity. 3. The structure of a particular embodiment is as follows: [Table 1] JPEG2024541018000011.jpg230164 [Brief description of the drawings]
[0017] [Figure 1] Effect of compound 14 on MDA-MB-231 cell cycle, where A is control, B is TNO155, C is abemaciclib, D is TNO155 + abemaciclib, E is Cmpd14 (1 μM), and F is Cmpd14 (6 μM). [Diagram 2]Effect of compound 14 on MDA-MB-468 cell cycle, where A is control, B is TNO155, C is abemaciclib, D is TNO155 + abemaciclib, E is Cmpd6 (1 μM), and F is Cmpd6 (6 μM). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Synthesis of intermediate 5-chloro-2-pyrazine sodium sulfide (II-1): [ka]
[0019] Step 1: Synthesis of Compound II-1-1 Compound 2,5-dichloropyrazine (5.00 g, 33.6 mmol), ethyl 3-mercaptopropionate (4.73 g, 1.05 eq.), potassium carbonate (4.64 g, 33.6 mmol) were placed in a 100 mL one-neck flask at room temperature, DMF (42 mL) was added, and the reaction was allowed to proceed for 4 h. When the raw material was completely converted as a result of monitoring by TLC plate, ethyl acetate was added, and the mixture was washed several times with saturated aqueous sodium chloride solution, and the organic phase was concentrated and purified by column chromatography to obtain compound II-1-1 (7.78 g, yield 94%).
[0020] Step 2: Synthesis of compound II-1 Compound II-1-1 (7.38 g, 30.0 mmol) was dissolved in THF and placed at 0°C. Sodium ethoxide (2.25 g, 33.0 mmol, 1.1 eq.) was added in batches. The reaction mixture was detected at room temperature to completely react the raw materials. The solid was filtered off to obtain compound II-1 (5.13 g, crude product).
[0021] Synthesis of intermediate (III-1): [ka]
[0022] Step 1: Synthesis of compound III-1-1 Nt-butoxycarbonyl-4-ethylformate piperidine (19.00g, 73.9mmol) was dissolved in THF, placed at -70℃, and LDA (1.28eq.) was slowly added dropwise. The reaction was allowed to proceed for 1.5h, and benzyl bromide (1.1eq.) was added, and the reaction was allowed to proceed for 2h while keeping the temperature high. As a result of monitoring by TLC plate, the raw material was completely converted, and then saturated ammonium chloride was slowly added dropwise to quench, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-1-1 (15.10g, yield 58%).
[0023] Step 2: Synthesis of compound III-1-2 Compound III-1-1 (12.00g, 34.6mmol) and PPA (1.35eq.) were placed in a 50mL single-neck flask and reacted at 150℃ for 3h. The reaction was monitored by TLC plate. When the raw materials were completely converted, the reaction system was adjusted to alkaline at low temperature using sodium hydroxide (2M), BOC anhydride (12.10g, 55.4mmol, 1.6eq.) was added, and the reaction was allowed to proceed overnight. The reaction was monitored by TLC plate. When the raw materials were completely converted, the reaction was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-1-2 (3.95g, yield 38%).
[0024] Step 3: Synthesis of compound III-1-3 Compound III-1-2 (4.80 g, 15.9 mmol), t-butylsulfonamide (4.05 g, 33.4 mmol, 2.1 eq.), and tetraethyl titanate (24 mL) were placed in a 100 mL one-neck flask and reacted at 120 ° C for 2 h. The reaction was monitored by TLC plate, and when the raw materials were completely converted, the reaction was placed at -50 ° C and BH3-THF (614.4 mg, 44.5 mmol, 2.8 eq.) was slowly added. After the addition was completed, the reaction was allowed to proceed at room temperature for 1 h. When the raw materials were completely converted, saturated ammonium chloride quenching was slowly added dropwise at -50 ° C. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-1-3 (3.10 g, yield 48%).
[0025] Step 4: Synthesis of compound III-1 III-1-3 (3.1 g, 7.64 mmol) was dissolved in DCM (30 mL), trifluoroacetic acid (9 eq.) was slowly added, and the reaction was allowed to proceed at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM, dried, and concentrated to give compound III-1 (2.30 g, 98% yield).
[0026] Synthesis of intermediate (III-2): [ka]
[0027] Step 1: Synthesis of compound (S)-2-((t-butyldimethylsilyl)oxy)ethyl propionate Compound (S)-ethyl 2-hydroxypropionate (40g, 338.6mmol), TBSCI (76.6g, 507.9mmol, 1.5eq.), imidazole (461g, 677.2mmol, 2.0eq) were dissolved in DCM and reacted at room temperature overnight. When the raw material was completely converted as monitored by TLC plate, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound (S)-ethyl 2-((t-butyldimethylsilyl)oxy)propionate (90.00g, crude).
[0028] Step 2: Synthesis of compound (S)-2-(t-butyldimethylsilyl)oxy)propionaldehyde At -78°C, DIBAL-H (361.9mL, 361.9mmol, 1.3eq.) was slowly added dropwise to a solution of the compound (S)-2-((t-butyldimethylsilyl)oxy)ethyl propionate (70.7g, 304.4mmol) in hexane (650mL), and reacted for 1h, then reacted at 0°C for 30min. After monitoring that the reaction was complete, the mixture was stirred at -78°C, quenched by slowly adding potassium sodium tartrate (aq.), extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain the compound (S)-2-(t-butyldimethylsilyl)oxy)propionaldehyde (38.6g, 41% yield for two steps).
[0029] Step 3: Synthesis of compound III-2-1 Compound Nt-butoxycarbonyl-4-piperidine-ethyl formate (101.5 g, 394.5 mmol, 1.0 eq.) was dissolved in THF (742 mL), LDA (295.9 mL, 591.8 mmol, 1.5 eq.) was slowly added dropwise at 0 ° C., and compound (S)-2-(t-butyldimethylsilyl)oxy)propionaldehyde (74.3 g, 394.5 mmol) was added in batches and reacted at room temperature for 1.5 h. As a result of monitoring by TLC plate, the raw material was completely converted, quenched, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-2-1 (163.4 g, yield 93%).
[0030] Step 4: Synthesis of compound III-2-2 LiBH4 (12 g, 550.2 mmol, 1.5 eq.) was added batchwise to a solution of compound III-2-1 (163.35 g, 366.8 mmol) in THF (700 mL) at 0 °C. After the addition was complete, the reaction was allowed to proceed at room temperature overnight. After monitoring for completeness of the reaction, the reaction was stirred at 0 °C, quenched by slow dropwise addition of NH4Cl (aq.), extracted with DCM, dried over anhydrous sodium sulfate and concentrated to give compound III-2-2 (103.7 g, 70% yield).
[0031] Step 5: Synthesis of compound III-2-3 Compound III-2-2 (103.7 g, 257.1 mmol) and TBAF (282.9 mL, 282.9 mmol, 1.1 eq.) were dissolved in THF (500 mL) and reacted at room temperature for 2 h. When the raw material was completely converted as monitored by TLC plate, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-2-3 (104.7 g, crude).
[0032] Step 6: Synthesis of compound III-2-4 Compound III-2-3 (104.7 g, 363.3 mmol) and TsCI (55.4 g, 290.6 mmol, 0.8 eq.) were dissolved in THF (600 mL), and sodium hydrogen (30.5 g, 127.2 mmol, 2.0 eq.) was slowly added at 0° C. and reacted for 1 h. As a result of monitoring by TLC plate, when the raw material was completely converted, it was quenched, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-2-4 (4.3.9 g, yield 63%).
[0033] Step 7: Synthesis of compound III-2-5 Compound III-2-4 (43.9 g, 161.9 mmol) was dissolved in DCM at 0°C, and Dess-Martin oxidant (89.3 g, 1.3 mmol) was added and reacted for 2 h. When the raw material was completely converted as monitored by TLC plate, it was quenched, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-2-5 (41.3 g, crude).
[0034] Step 8: Synthesis of compound III-2-6 Compound III-2-5 (41.3 g, 153.3 mmol), t-butylsulfonamide (37.2 g, 306.6 mmol, 2.0 eq.), titanium tetraethoxide (139.9 g, 613.2 mmol, 4.0 eq.) were dissolved in THF (300 mL), and a 100 mL one-neck flask was reacted at 90 ° C for 21 h. The reaction was monitored by TLC plate. When the raw materials were completely converted, LiBH4 (6.7 mg, 306.6 mmol, 2.0 eq.) was added at -4 ° C., dissolved in ethanol, and reacted at room temperature for 1 h. The reaction was monitored by TLC plate. When the raw materials were completely converted, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound III-2-6 (34.6 g, crude).
[0035] Step 9: Synthesis of intermediate III-2 III-2-6 (1 g, 2.67 mmol) was dissolved in DCM (10 mL), trifluoroacetic acid (2 mL) was slowly added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with ethyl acetate, dried, and concentrated to give compound III-2 (150.0 mg, total yield of 20% for three steps).
[0036] Synthesis of intermediate (I-1): [ka]
[0037] Step 1: Synthesis of compound I-1-2 Compound I-1-1 (17.60 g, 63.6 mmol), propionaldehyde diethyl acetal (12.20 mg, 95.4 mmol, 1.5 eq.), Pd(dppf)Cl2 (930.1 mg, 0.02 eq.), cuprous iodide (242.3 mg, 0.02 eq.) and triethylamine (1.5 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous THF (176 mL) was added and reacted at 60 ° C for 48 h. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound I-1-2 (6.61 g, 32% yield).
[0038] Step 2: Synthesis of compound I-1-3 Compound I-1-2 (6.30 g, 19.6 mmol) and TBAF (25.63 g, 98.0 mmol, 5.0 eq.) were dissolved in 2 mL of THF and reacted at 70° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound I-1-3 (8.50 g, crude).
[0039] Step 3: Synthesis of compound I-1-4 I-1-3 (8.50 g, 26.3 mmol) was dissolved in 2.0 mL of dioxane at room temperature, and concentrated hydrochloric acid (0.76 mL) was slowly added dropwise to react for 20 min. After monitoring that the reaction was complete, it was extracted with EA, dried and concentrated to give compound I-1-4 (3.10 g, 63% yield for two steps).
[0040] Step 4: Synthesis of compound I-1-5 I-1-4 (3.10 g, 12.4 mmol) was dissolved in 1.0 mL of DMF at room temperature, potassium hydrogen sulfate (760.0 mg, 5.58 mmol, 0.45 eq.) was added, and the reaction was carried out for 6 h. As a result of monitoring by TLC plate, the raw material was completely converted. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound I-1-5 (5.20 g, crude).
[0041] Step 5: Synthesis of compound I-1-6 Compound I-1-5 (5.20 g, 19.6 mmol), HBTU (7.43 g, 19.6 mmol, 1.0 eq.), DIPEA (7.60 g, 58.8 mmol, 3.0 eq.) were added to a sealed tube, and under nitrogen protection, DMF (1.7 mL) was added and reacted for 30 min. The reaction was monitored by TLC plate, and when the raw material was completely converted, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound I-1-6 (1.50 g, 31% yield for two stages).
[0042] Example 1 [ka] Step 1: Synthesis of compound 1-1 Compound 2,5-dichloropyrazine (1.50 g, 10.08 mmol), ethyl 3-mercaptopropionate (1.35 g, 10.08 mmol, 1.0 eq.), potassium carbonate (1.53 g, 11.1 mmol, 1.1 eq.) were placed in a 50 mL one-neck flask at room temperature, DMF (15 mL) was added, and the reaction was carried out for 3 h. As a result of monitoring by TLC plate, when the raw material was completely converted, ethyl acetate was added, and the mixture was washed several times with saturated aqueous sodium chloride solution, and the organic phase was combined and concentrated, and purified by column chromatography to obtain compound 1-1 (2.51 g, 76% yield). Step 2: Synthesis of compound 1-2 Intermediate 1-1 (1.82 g, 7.37 mmol), 4-methyl-4-(Nt-butoxycarbonyl)aminopiperidine (1.74 g, 8.1 mmol, 1.1 eq.) were dissolved in NMP and stirred overnight at 95° C. After monitoring for complete reaction, it was diluted with ethyl acetate, washed five times with saturated saline, concentrated the organic phase, and separated by column chromatography to give compound 1-2 (969.2 mg, 31% yield). Step 3: Synthesis of compounds 1-3 1-2 (969.2 mg, 2.28 mmol) was dissolved in ethanol, and sodium ethoxide (170.8 mg, 2.51 mmol, 1.1 eq.) was added in a batchwise manner. The reaction was detected at room temperature, and the raw materials were completely reacted. The solid was filtered off to obtain compound 1-3 (674.1 mg, 85% yield). Step 4: Synthesis of Compounds 1-4 Intermediate I-1 (99.6 mg, 0.34 mmol), compound 1-3 (118.3 mg, 0.34 mmol), Pd2(dba)3 (6.2 mg, 2 mol%), XantPhos (23.1 mg, 4 mol%), and DIPEA (87.9 mg, 0.68 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (2 mL) was added and reacted at 90° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 1-4 (40.4 mg, 21% yield). Step 5: Synthesis of Compound 1 Compound 1-4 (20.2 mg, 0.035 mmol) was dissolved in EA (1 mL), EA / HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 1 (14.2 mg, 87% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.75 (s, 1H), 8.35 (d, J = 1.4 Hz, 1H), 8.21 (d, J = 1.4 Hz, 1H), 6.43 (s, 1H), 4.56 (p, J = 8.8 Hz, 1H), 3.85 - 3.63 (m, 4H), 3.10 (d, J = 17.1 Hz, 6H), 2.26 - 2.10 (m, 2H), 1.94 - 1.83 (m, 2H), 1.73 - 1.40 (m, 8H), 1.24 (s, 3H).
[0043] Example 2 [ka] Step 1: Synthesis of compound 2-2 Compound 1-3 (240.0 mg, 0.69 mmol), 2-amino-5-iodopyridine (151.8 mg, 0.69 mmol, 1.0 eq.), Pd2(dba)3 (12.6 mg, 2 mol%), XantPhos (16.0 mg, 4 mol%), and DIPEA (178.4 mg, 1.4 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (3 mL) was added and reacted at 105° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 2-2 (49.8 mg, 17% yield). Step 2: Synthesis of compound 2-3 Compound 2-2 (89.9 mg, 0.22 mmol), intermediate I-1 (70.3 mg, 0.24 mmol, 1.1 eq.), Pd2(dba)3 (4.0 mg, 2 mol%), BINAP (8.2 mg, 6 mol%), and DIPEA (178.4 mg, 1.4 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1 mL) was added and reacted at 105 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 2-3 (90.2 mg, 61% yield). Step 3: Synthesis of compound 2 Compound 2-3 (62.0 mg, 0.09 mmol) was dissolved in EA (1 mL), EA / HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 2-4 (35.2 mg, 68% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.72 (s, 1H), 8.49 (d, J = 8.8 Hz, 1H), 8.41 (d, J = 2.3 Hz, 1H), 8.07 (d, J = 1.4 Hz, 2H), 8.04 (d, J = 1.4 Hz, 1H), 7.83 (dd, J = 8.8, 2.3 Hz, 1H), 6.46 (s, 1H), 4.79 (p, J = 9.4 Hz, 1H), 3.71 -3.52 (m, 4H), 3.16 (s, 6H), 2.64 - 2.47 (m, 2H), 2.16 - 1.96 (m, 4H), 1.77 - 1.69 (m, 2H), 1.69 - 1.46 (m, 4H), 1.20 (s, 3H).
[0044] Example 3 [ka] Step 1: Synthesis of compound 3-1 Compound 3-chloro-4-iodoaniline (700.0 mg, 2.8 mmol), 5-chloro-2-pyrazine sodium sulfide (472.1 mg, 2.8 mmol, 1.0 eq.), Pd2(dba)3 (18.3 mg, 2 mol%), XantPhos (23.1 mg, 4 mol%), DIPEA (724.1 mg, 5.6 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (10 mL) was added and reacted at 100 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 3-1 (226.1 mg, 30% yield). Step 2: Synthesis of compound 3-3 Compound 3-1 (150.0 mg, 0.55 mmol) and compound 3-2 (337.2 mg, 1.1 mmol, 2.0 eq.) were dissolved in NMP and stirred overnight at 100° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to obtain compound 3-3 (116.6 mg, 39% yield). Step 3: Synthesis of Compound 3-4 Compound 3-4 (100.0 mg, 0.18 mmol), intermediate I-1 (1.1 eq.), Pd2(dba)3 (18.3 mg, 2 mol%), BINAP (6.7 mg, 6 mol%), and DIPEA (46.5 mg, 0.36 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1 mL) was added and reacted at 100° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 3-4 (67.0 mg, 47% yield). Step 4: Synthesis of compound 3 Compound 3-4 (60.0 mg, 0.075 mmol) was dissolved in EA (1 mL), EA / HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 3 (42.2 mg, 81% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.65 (s, 1H), 8.25 (d, J = 2.3 Hz, 1H), 8.11 (d, J = 1.4 Hz, 1H), 8.08 (d, J = 1.4 Hz, 1H), 7.37 - 7.27 (m, 3H), 7.25 - 7.18 (m, 4H), 6.44 (s, 1H), 4.74 (p, J = 9.2 Hz, 1H), 4.21 - 4.09 (m, 2H), 3.98 (s, 1H), 3.27 - 3.13 (m, 8H), 3.08 (d, J = 15.7 Hz, 1H), 2.72 (d, J = 15.7 Hz, 1H), 2.67 - 2.52 (m, 2H), 2.17 - 2.00 (m, 4H), 1.91 - 1.62 (m, 5H), 1.42 - 1.33 (m, 1H).
[0045] Example 4 [ka] Step 1: Synthesis of compound 4-2 Compound 4-1 (100.0 mg, 0.22 mmol), intermediate I-1 (67.6 mg, 0.23 mmol, 1.05 eq.), Pd2(dba)3 (36.6 mg, 4 mol%), BINAP (74.7 mg, 12 mol%), and Cs2CO3 (143.4 mg, 0.44 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1 mL) was added and reacted at 100° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 4-2 (41.0 mg, 26% yield). Step 2: Synthesis of compound 4 Compound 4-2 (41.0 mg, 0.060 mmol) was dissolved in EA (1 mL), EA / HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 4 (21.0 mg, 60% yield).1 H NMR (300 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.31 (d, J = 1.4 Hz, 1H), 8.27 (d, J = 1.4 Hz, 1H), 8.06 (d, J = 5.4 Hz, 1H), 7.74 (s, 1H), 6.47 (s, 1H), 6.35 (d, J = 5.4 Hz, 1H), 4.78 (p, J = 8.7 Hz, 1H), 3.92 - 3.80 (m, 2H), 3.78 - 3.65 (m, 2H), 3.17 (s, 3H), 3.14 (s, 3H), 2.53 - 2.36 (m, 2H), 2.14 - 1.92 (m, 4H), 1.76 - 1.59 (m, 6H), 1.27 (s, 3H).
[0046] Example 5 [ka] Step 1: Synthesis of compound 5-2 Intermediate III-1 (300.0 mg, 1.10 mmol) and compound 5-1 (450.6 mg, 1.65 mmol, 1.5 eq.) were dissolved in NMP, DIPEA (10 mL) was added, and the mixture was stirred at 100° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 5-2 (444.0 mg, 74% yield). Step 2: Synthesis of compound 5-3 Compound 5-2 (150.0 mg, 0.28 mmol), intermediate I-1 (84.9 mg, 0.29 mmol, 1.05 eq.), Pd2(dba)3 (10.3 mg, 4 mol%), BINAP (20.9 mg, 12 mol%), and Cs2CO3 (182.4 mg, 0.56 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1 mL) was added and reacted at 100° C. overnight. After monitoring for complete reaction, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 5-3. Step 3: Synthesis of compound 5 Compound 5-3 was dissolved in EA (1 mL), EA·HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 5 (29.0 mg, 20% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.79 (s, 1H), 8.30 (d, J = 1.2 Hz, 1H), 8.27 (d, J = 1.2 Hz, 1H), 8.05 (d, J = 5.4 Hz, 1H), 7.74 (s, 1H), 7.38 - 7.31 (m, 1H), 7.26 - 7.20 (m, 3H), 6.45 (s, 1H), 6.35 (d, J = 5.4 Hz, 1H), 4.76 (p, J = 8.8 Hz, 1H), 4.38 - 4.19 (m, 2H), 4.02 (s, 1H), 3.38 - 3.22 (m, 2H), 3.20 - 3.06 (m, 7H), 2.77 (d, J = 15.7 Hz, 1H), 2.54 - 2.36 (m, 2H), 2.13 -1.75 (m, 9H), 1.48 - 1.38 (m, 1H).
[0047] (Examples 6 and 7) [ka] Step 1: Synthesis of compound 6-2 Compound 6-1 (191.0 mg, 0.66 mmol) was dissolved in DCM (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was allowed to react at room temperature for 3 h. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 6-2 (137.1 mg). Step 2: Synthesis of compound 6-3 Compound 6-2 (137.1 mg, 0.51 mmol), intermediate 5-1 (120.9 mg, 0.51 mmol, 1.0 eq.), and cesium carbonate (498.5 mg, 1.53 mmol, 3.0 eq.) were dissolved in DMSO (3 mL) and stirred overnight at 90° C. After monitoring for complete reaction, it was diluted with ethyl acetate, washed five times with saturated brine, and the organic phase was concentrated and separated by column chromatography to give compound 6-3 (66.7 mg, 20% yield). Step 3: Synthesis of compounds 6-4 and 6-5 Compound 6-3 (66.7 mg, 0.13 mmol), intermediate I-1 (58.6 mg, 0.20 mmol, 1.5 eq.), Pd2(dba)3 (2.4 mg, 2 mol%), BINAP (4.9 mg, 6 mol%), and DIPEA (33.6 mg, 0.26 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1 mL) was added and reacted at 100 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compounds 6-4 (24.6 mg, 24% yield) and 6-5 (18.9 mg). Step 4: Synthesis of compounds 6 and 7 Compound 6-4 (24.6 mg, 0.032 mmol) was dissolved in EA (1 mL), EA·HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to make the mixture alkaline, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 6 (14.5 mg, 68% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.78 (s, 1H), 8.26 (d, J = 1.4 Hz, 1H), 8.24 (d, J = 1.4 Hz, 1H), 8.02 (d, J = 5.5 Hz, 2H), 7.46 - 7.21 (m, 4H), 6.46 (s, 1H), 6.35 (d, J = 5.5 Hz, 2H), 5.05 (d, J = 15.2 Hz, 1H), 4.86 - 4.67 (m, 2H), 4.49 -4.40 (m, 1H), 4.27 - 4.03 (m, 2H), 3.14 (s, 3H), 3.12 (s, 3H), 2.53 - 2.33 (m, 2H), 2.31 - 2.16 (m, 1H), 2.04 - 1.86 (m, 5H), 1.71 - 1.48 (m, 2H). Compound 6-5 (18.9 mg, 0.019 mmol) was obtained as described above, and compound 7 (11.4 mg, yield 70%) was obtained. 1 H NMR (300 MHz, Chloroform-d) δ 8.85 (s, 2H), 8.25 (s, 2H), 8.11 (d, J = 5.3 Hz, 1H), 7.45 - 7.36 (m, 2H), 7.33 - 7.18 (m, 2H), 6.60 (d, J = 5.3 Hz, 1H), 6.46 (s, 2H), 5.05 (d, J = 15.1 Hz, 1H), 4.74 (d, J = 15.1 Hz, 1H), 4.69 - 4.59 (m, 2H), 4.54 - 4.44 (m, 1H), 4.21 - 4.06 (m, 2H), 3.21 - 2.98 (m,12H), 2.30 - 2.07 (m, 6H), 2.02 - 1.82 (m, 6H), 1.51 - 1.27 (m, 6H).
[0048] (Example 8)
change
[0049] Example 9 [ka] Step 1: Synthesis of compound 6-(Nt-butoxycarbonyl)amino-2-chloro-3-iodopyridine Compound 5-amino-2-chloro-3-iodopyridine (733.0 mg, 2.88 mmol) was dissolved in DCM, triethylamine (349.1 mg, 3.46 mmol, 1.2 eq.), DMAP (17.6 mg, 0.14 mmol, 0.05 eq.) were added, and BOC anhydride (690.6 mg, 3.17 mmol, 1.1 eq.) was added at 0°C, and the mixture was reacted at room temperature for 3 h. After monitoring that the reaction was complete, the mixture was washed several times with saturated aqueous sodium chloride solution, and the organic phase was concentrated, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 6-(Nt-butoxycarbonyl)amino-2-chloro-3-iodopyridine (513.2 mg, 50% yield). Step 2: Synthesis of compound 9-1 Compound 6-(Nt-butoxycarbonyl)amino-2-chloro-3-iodopyridine (1.28 g, 3.62 mmol), compound 5-chloro-2-pyrazine sodium sulfide (669.0 mg, 3.98 mmol, 1.1 eq.), Pd2(dba)3 (66.2 mg, 2 mol%), Xantphos (125.5 mg, 6 mol%), DIPEA (934.0 mg, 7.24 mmol, 2 eq) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 9-1 (0.85 g, 65% yield). Step 3: Synthesis of compound 9-2 Compound 9-1 (0.80 g, 2.15 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 9-2 (0.55 g, 94% yield). Step 4: Synthesis of compound 9-3 Intermediate III-1 (80.0 mg, 0.29 mmol) and compound 9-2 (99.0 mg, 0.32 mmol, 1.0 eq.) were dissolved in 1.0 ml of NMP, DIPEA (10 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 9-3 (128.0 mg, 80% yield). Step 5: Synthesis of compound 9-4 Compound 9-4 (100 mg, 0.18 mmol), intermediate I-1 (56.6 mg, 0.19 mmol, 1.05 eq.), Pd2(dba)3 (7 mg, 2 mol%), BINAP (14 mg, 5 mol%), and cesium carbonate (120 mg, 0.37 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (2.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 9-4 (53.3 mg, 37% yield). Step 6: Synthesis of compound 9 Compound 9-4 (33.0 mg, mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to make the mixture alkaline, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 9 (24.1 mg, 83% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.83 (s, 1H), 8.45 (s, 1H), 8.42 (d, J = 8.6 Hz, 1H), 8.15 (d, J = 1.3 Hz, 1H), 8.09 (d, J = 1.3 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.39 - 7.29 (m, 1H), 7.26 - 7.17 (m, 3H), 6.48 (s, 1H), 4.79 (p, J = 9.0 Hz, 1H), 4.25 - 4.09 (m, 2H), 3.98 (s, 1H), 3.29 - 3.12 (m, 8H), 3.08 (d, J = 15.6 Hz, 1H), 2.73 (d, J = 15.6 Hz, 1H), 2.63 - 2.44 (m, 2H), 2.17 - 1.94 (m, 4H), 1.92 - 1.61 (m, 5H), 1.42 - 1.33 (m, 1H).
[0050] Example 10 [ka] Step 1: Synthesis of compound 10-1 Compound 8-2 (150 mg, 0.28 mmol), compound 11-5 (98 mg, 0.3 mmol, 1.1 eq.), Pd2(dba)3 (11 mg, 4 mol%), Xantphos (22 mg, 12 mol%), and cesium carbonate (180 mg, 0.55 mmol, 2.0 eq) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (2.0 mL) was added and reacted at 110 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 10-1 (132 mg, 57% yield). Step 2: Synthesis of compound 10 Compound 10-1 (102.0 mg, 0.12 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 10 (74.7 mg, 57% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.50 (d, J = 3.7 Hz, 1H), 8.32 (d, J = 1.0 Hz, 1H), 8.27 (s, 1H), 8.19 (d, J = 1.0 Hz, 1H), 8.12 (d, J = 5.4 Hz, 1H), 7.97 (s, 1H), 7.82 (d, J = 11.9 Hz, 1H), 7.53 (d, J = 6.6 Hz, 1H), 7.32 (m, 3H), 6.40 (d, J = 5.4 Hz, 1H), 4.73 (p, J = 7.0 Hz, 1H), 4.30 - 4.06 (m, 3H), 3.43 - 3.14 (m, 3H), 2.89 (d, J = 16.2 Hz, 1H), 2.68 (s, 3H), 1.97 - 1.50 (m, 10H).
[0051] Example 11 [ka] Step 1: Synthesis of compound 6-amino-2-cyanopyridine Compound 2-bromo-6-aminopyridine (5.00 g, 28.9 mmol), zinc cyanide (3.97 g, 33.8 mmol, 1.17 eq.), and tetrakis(triphenylphosphine)palladium (668.0 mg, 2 mol%) were placed in a 50 mL one-neck flask, protected with nitrogen, and then DMF (mL) was added and reacted at 100° C. for 2 h. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 6-amino-2-cyanopyridine (2.22 g, 64% yield). Step 2: Synthesis of compound 3-bromo-6-amino-2-cyanopyridine Compound 6-amino-2-cyanopyridine (2.22 g, 18.63 mmol), tetrabutylammonium tribromide (10.33 g, 21.43 mmol), ethanol (15.0 mL), and DCM (15.0 mL) were placed in a 100 mL single-neck flask and reacted at room temperature overnight. After monitoring the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 3-bromo-6-amino-2-cyanopyridine (1.92 g, 52% yield). Step 3: Synthesis of compound 11-1 Compound 3-bromo-6-amino-2-cyanopyridine (1.92 g, 9.7 mmol), compound ethyl 3-mercaptopropionate (3.9 g, 29.1 mmol, 3 eq.), Pd2(dba)3 (178 mg, 2 mol%), Xantphos (337 mg, 6 mol%), DIPEA (3.4 mL, 19.4 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 105 ° C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 11-1 (1.82 g, 75% yield). Step 4: Synthesis of compound 11-2 Compound 11-1 (1.82 g, mmol), sodium ethoxide (641 mg, 9.4 mmol, 1.3 eq.), and ethanol (mL) were placed in a 100 mL one-neck flask and reacted at room temperature overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 11-2 (1.67 g, crude). Step 5: Synthesis of compound 11-3 At room temperature, compound 11-2 (1.54 g, 8.9 mmol), compound 2,5-dichloropyrazine (1.3 g, 8.9 mmol, 1.0 eq.), and potassium carbonate (9.4 g, 9.8 mmol, 1.1 eq.) were dissolved in 10 mL of DMF and reacted at room temperature for 12 h. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 11-3 (510.0 mg, 22% yield). Step 6: Synthesis of compound 11-4 Compound III-3 (200.0 mg, 0.76 mmol), t-butyl(4-methylpiperidine)formamide (162.9 mg, 0.84 mmol, 1.1 eq.) were dissolved in 3.0 mL of NMP, DIPEA (8.0 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated brine, and the organic phase was concentrated and separated by column chromatography to give compound 11-4 (254.0 mg, 76% yield). Step 7: Synthesis of compound 11-5 Compound 11-4 (200.0 mg, 0.45 mmol, 0.45 eq), compound 11-5 (322.7 mg, 1.0 mmol, 1.0 eq.), Pd2(dba)3 (16.5 mg, 4 mol%), Xantphos (69.4 mg, 12 mol%), and cesium carbonate (651.6 mg, 2.0 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (4.0 mL) was added and reacted at 110 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 11-5 (70.6 mg, 22% yield). Step 7: Synthesis of compound 11 Compound 11-5 (65.0 mg, 0.09 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 11 (38.0 mg, 67% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.65 (d, J = 9.0 Hz, 1H), 8.50 (d, J = 3.6 Hz, 2H), 8.24 (d, J = 1.3 Hz, 1H), 8.15 (d, J = 1.0 Hz, 1H), 8.07 (d, J = 1.3 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.75 (d, J = 11.6 Hz, 1H), 4.74 (p, J = 7.0 Hz, 1H), 3.78 - 3.55 (m, 4H), 2.70 (s, 3H), 1.72 (s, 3H), 1.69 (s, 3H), 1.68 - 1.47 (m, 4H), 1.21 (s, 3H).
[0052] Example 12 [ka] Step 1: Synthesis of compound 12-1 Intermediate III-2 (865.9 mg, 0.91 mmol, 1.2 eq.) and compound 11-3 (200.0 mg, 0.76 mmol) were dissolved in NMP (3.0 mL), DIPEA (8.0 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 12-1 (162.2 mg, 43% yield). Step 2: Synthesis of compound 12-2 Compound 12-1 (150.0 mg, 0.30 mmol), compound 11-5 (96.8 mg, 0.3 mmol, 1.0 eq.), Pd2(dba)3 (10.1 mg, 4 mol%), Xantphos (20.8 mg, 12 mol%), and cesium carbonate (195.5 mg, 0.6 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (2.0 mL) was added and reacted at 110 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 12-2 (123.0 mg, 52% yield). Step 3: Synthesis of compound 12 Compound 12-2 (123.0 mg, 0.16 mmol) was dissolved in EA (1 mL), EA / HCl (2 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 12 (37.1 mg, 64% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.65 (d, J = 9.0 Hz, 1H), 8.49 (d, J = 3.7 Hz, 1H), 8.43 (s, 1H), 8.24 (d, J = 1.2 Hz, 1H), 8.15 (d, J = 1.0 Hz, 1H), 8.06 (d, J = 1.2 Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.75 (d, J = 11.8 Hz, 1H), 4.74 (p, J = 7.0 Hz, 1H), 4.24 - 4.13 (m, 1H), 3.96 - 3.75 (m, 3H), 3.68 (d, J = 8.8 Hz, 1H), 3.50 - 3.26 (m, 2H), 2.99 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.93 - 1.80 (m, 1H), 1.77 - 1.64 (m, 9H), 1.23 (d, J = 6.4Hz, 3H).
[0053] Example 13 [ka] Step 1: Synthesis of compound 13-1 5-Nitro-2,3-dichloropyridine (500.0 mg, 2.59 mmol, 1.2 eq.), 5-chloro-2-pyrazine sodium sulfide (524.0 mg, 3.11 mmol) were dissolved in NMP (6 mL), K2CO3 (716.0 mg, 5.18 mmol, 2 eq.) was added, and the mixture was stirred at room temperature overnight. After monitoring the reaction was complete, it was diluted with ethyl acetate, washed five times with saturated brine, and the organic phase was concentrated and separated by column chromatography to give compound 13-3 (526.0 mg, 67% yield). Step 2: Synthesis of compound 13-2 Compound 13-1 (400.0 mg, 1.32 mmol), iron powder (295.7 mg, 5.28 mmol, 4.0 eq.), acetic acid (4.0 mL), and water (4.0 mL) were placed in a 25 mL one-neck flask and reacted at room temperature for 12 h. After monitoring that the reaction was complete, it was quenched by dropping dilute hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 13-2 (318.0 mg, 88% yield). Step 3: Synthesis of compound 13-3 Intermediate III-2 (865.9 mg, 0.91 mmol, 1.2 eq.) and compound 13-2 (300.0 mg, 1.10 mmol) were dissolved in 4.0 mL of NMP, DIPEA (10.0 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 13-3 (340.7 mg, 61% yield). Step 4: Synthesis of compound 13-4 Compound 13-3 (108.0 mg, 0.33 mmol), compound 11-5 (106.5 mg, 0.33 mmol, 1.0 eq.), Pd2(dba)3 (12.1 mg, 4 mol%), Xantphos (22.9 mg, 12 mol%), and cesium carbonate (215.0 mg, 0.66 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (2.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 13-4 (144.0 mg, 54% yield). Step 5: Synthesis of compound 13 Compound 13-4 (43.0 mg, 0.05 mmol) was dissolved in EA (1 mL), EA / HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 13 (13.3 mg, 35% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.46 (d, J = 2.4 Hz, 1H), 8.37 (d, J = 3.7 Hz, 1H), 8.30 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 1.2 Hz, 1H), 8.19 (d, J = 1.2 Hz, 1H), 8.11 (d, J = 1.1 Hz, 1H), 7.73 (d, J = 11.7 Hz, 1H), 7.33 (s, 1H), 4.74 (p, J = 6.9 Hz, 1H), 4.26 - 4.14 (m, 1H), 4.01 - 3.87 (m, 2H), 3.82 (d, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.54 - 3.31 (m, 2H), 3.00 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.95 - 1.83 (m, 1H), 1.80 - 1.64 (m, 9H), 1.25 (d, J = 6.4 Hz, 3H).
[0054] Example 14 [ka] Step 1: Synthesis of compound 14-1 Intermediate III-2 (282.0 mg, 1.27 mmol) and compound 5-1 (278.6 mg, 1.02 mmol, 0.8 eq.) were dissolved in 4.0 mL of NMP, DIPEA (10.0 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 14-1 (151 mg, 23% yield). Step 2: Synthesis of compound 14-2 Compound 14-1 (131.0 mg, 0.26 mmol), compound 11-5 (83.9 mg, 0.26 mmol, 1.0 eq.), Pd2(dba)3 (9.5 mg, 4 mol%), Xantphos (18.1 mg, 12 mol%), and cesium carbonate (169.4 mg, 0.52 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (4.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 14-2 (59.6 mg, 70% yield). Step 3: Synthesis of compound 14 Compound 14-2 (59.6 mg, 0.07 mmol) was dissolved in EA (1 mL), EA·HCl (1 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 14 (39.2 mg, 64% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.50 (d, J = 3.7 Hz, 1H), 8.31 (d, J = 1.3 Hz, 1H), 8.25 (d, J = 1.4 Hz, 1H), 8.20 (d, J = 1.3 Hz, 1H), 8.10 (d, J = 5.3 Hz, 1H), 7.93 (s, 1H), 7.82 (d, J = 11.8 Hz, 1H), 6.38 (d, J = 5.3 Hz, 1H), 4.73 (p, J = 6.9 Hz, 1H), 4.25 - 4.16 (m, 1H), 4.05 - 3.90 (m, 2H), 3.84 (d, J = 8.8 Hz, 1H), 3.71 (d, J = 8.8 Hz, 1H), 3.61 - 3.37 (m, 2H), 3.02 (d, J = 4.6 Hz, 1H), 2.69 (s, 3H), 1.97 - 1.87 (m, 1H), 1.82 - 1.67 (m, 9H), 1.25 (d, J = 6.4 Hz, 3H).
[0055] Example 15 [ka] Step 1: Synthesis of compound 15-1 Intermediate III-2 (301.8 mg, 1.1 mmol, 2.5 eq.) and compound 9-2 (120.0 mg, 0.44 mmol) were dissolved in 3.0 mL of NMP, DIPEA (1.0 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 15-1 (92.5 mg, 41% yield). Step 2: Synthesis of compound 15-2 Compound 15-1 (80.0 mg, 0.16 mmol), compound 11-5 (51.6 mg, 0.16 mmol, 1 eq.), Pd2(dba)3 (2.9 mg, 2 mol%), Xantphos (5.6 mg, 6 mol%), and cesium carbonate (104.3 mg, 0.32 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 105 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 15-2 (71.0 mg, 56% yield). Step 3: Synthesis of compound 15 Compound 15-2 (71.0 mg, 0.09 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to make the mixture alkaline, and the mixture was extracted with DCM / MeOH (5:1), dried, and concentrated to give compound 14 (29.4 mg, 47% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.47 (d, J = 3.8 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.29 (s, 1H), 8.17 (d, J = 1.4 Hz, 1H), 8.16 (d, J = 1.2 Hz, 1H), 8.10 (d, J = 1.4 Hz, 1H), 7.75 (d, J = 11.5 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 4.73 (p, J = 6.9 Hz, 1H), 4.26 - 4.11 (m, 1H), 3.96 - 3.76 (m, 3H), 3.69 (d, J = 8.7 Hz, 1H), 3.49 - 3.27 (m, 2H), 2.99 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.96 - 1.79 (m, 2H), 1.71 (s, 3H), 1.69 (s, 3H), 1.38 - 1.27 (m, 2H), 1.24 (d, J = 6.4 Hz, 3H).
[0056] (Example 16) [ka] Step 1: Synthesis of compound 16-1 Compound 9-2 (150.0 mg, 0.55 mmol) and compound 4-methyl-4-(Nt-butoxycarbonyl)aminopiperidine (201.4 mg, 0.94 mmol, 1.7 eq.) were dissolved in 1 mL of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to obtain compound 16-1 (165.5 mg, 67% yield). Step 2: Synthesis of compound 16-2 Compound 16-1 (120.0 mg, 0.27 mmol), intermediate I-1 (79.1 mg, 0.27 mmol, 1.0 eq.), Pd2(dba)3 (14.8 mg, 2 mol%), BINAP (8.4 mg, 5 mol%), and cesium carbonate (175.9 mg, 0.54 mmol, 2.0 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1.0 mL) was added and reacted at 100° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 16-2 (20.0 mg, 10% yield). Step 3: Synthesis of compound 16 Compound 16-2 (20.0 mg, 0.03 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 16 (14.1 mg, 77% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.77 (s, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.21 (s, 1H), 8.15 (d, J = 1.3 Hz, 1H), 8.08 (d, J = 1.3 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 6.47 (s, 1H), 4.78 (p, J = 9.0 Hz, 1H), 3.75 - 3.54 (m, 4H), 3.16 (s, 6H), 2.61 - 2.43 (m, 2H), 2.16 - 1.95 (m, 4H), 1.80 - 1.45 (m, 6H), 1.21 (s, 3H).
[0057] (Example 17) [ka] Step 1: Synthesis of compound 17-1 Compound 6-amino-3-chloro-4-bromopyridine (200.0 mg, 0.96 mmol), 5-chloro-2-mercaptopyrazine (155.4 mg, 1.06 mmol, 1.1 eq.), Pd2(dba)3 (17.6 mg, 2 mol%), Xantphos (33.3 mg, 6 mol%), DIPEA (248.3 mg, 1.92 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1.0 mL) was added and reacted at 95° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 17-1 (95.6 mg, 36% yield). Step 2: Synthesis of compound 17-2 Compound 17-1 (95.6 mg, 0.35 mmol) and intermediate III-2 (107.0 mg, 0.39 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 17-2 (98.8 mg, 55% yield). Step 3: Synthesis of compound 17-3 Compound 17-2 (95.0 mg, 0.19 mmol), 11-5 (67.8 mg, 0.21 mmol, 1.1 eq.), Pd2(dba)3 (3.5 mg, 2 mol%), Xantphos (6.6 mg, 6 mol%), and DIPEA (49.1 mg, 0.38 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1.0 mL) was added and reacted at 95 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 17-3 (66.3 mg, 44% yield). Step 4: Synthesis of compound 17 Compound 17-3 (61.0 mg, 0.076 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 17 (38.2 mg, 73% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.26 (d, J = 1.3 Hz, 1H), 8.17 (d, J = 3.6 Hz, 1H), 8.15 (s, 1H), 8.09 (d, J = 1.3 Hz, 1H), 8.04 (s, 1H), 7.98 (s, 1H), 7.73 (s, 1H), 7.64 (d, J = 11.5 Hz, 1H), 4.75 (p, J = 7.0 Hz, 1H), 4.24 - 4.15 (m, 1H), 3.90 - 3.75 (m, 3H), 3.68 (d, J = 8.8 Hz, 1H), 3.45 - 3.24 (m, 2H), 3.00 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.92 - 1.80 (m, 1H), 1.75 - 1.61 (m, 9H), 1.25 (d, J = 6.4 Hz, 3H).
[0058] (Example 18) [ka] Step 1: Synthesis of compound 18-1 Compound 2-amino-5-bromopyrazine (400.0 mg, 2.30 mmol), 5-chloro-2-pyrazine sodium sulfide (426.6 mg, 2.53 mmol, 1.1 eq.), Pd2(dba)3 (42.1 mg, 2 mol%), Xantphos (79.8 mg, 6 mol%), DIPEA (594.8 mg, 4.60 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1.0 mL) was added and reacted at 90 ° C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 18-1 (161.7 mg, 29% yield). Step 2: Synthesis of compound 18-2 Compound 18-1 (120.0 mg, 0.50 mmol) and intermediate III-2 (150.9 mg, 0.55 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 18-2 (76.3 mg, 32% yield). Step 3: Synthesis of compound 18-3 Compound 18-2 (76.3 mg, 0.16 mmol), compound 11-5 (58.1 mg, 0.18 mmol, 1.1 eq.), Pd2(dba)3 (2.9 mg, 2 mol%), BINAP (6.0 mg, 6 mol%), and sodium t-butoxide (30.8 mg, 0.32 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 90 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 18-3 (10.2 mg, 9% yield). Step 4: Synthesis of compound 18 Compound 18-3 (10.2 mg, 0.014 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 18 (7 mg, 75% yield). 1 H NMR (300 MHz, Chloroform-d) δ 9.62 (d, J = 1.6 Hz, 1H), 8.43 (d, J = 3.7 Hz, 1H), 8.30 (d, J = 1.4 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 8.16 (d, J = 1.4 Hz, 1H), 8.14 (d, J = 1.5 Hz, 1H), 8.01 (s, 1H), 7.76 (d, J = 11.4 Hz, 1H), 4.73 (p, J = 5.9, 4.8 Hz, 1H), 4.23 - 4.13 (m, 1H), 4.01 - 3.77 (m, 3H), 3.70 (d, J = 8.8 Hz, 1H), 3.52 - 3.30 (m, 2H), 3.01 (d, J = 4.5 Hz, 1H), 2.69 (s, 3H), 1.93 - 1.82 (m, 1H), 1.70 (m, J = 6.9 Hz, 9H), 1.24 (d, J = 6.4 Hz, 3H).
[0059] (Example 19) [ka] Step 1: Synthesis of compound 2-amino-4-chloro-3-cyanopyridine Compound 2-amino-4-chloro-3-iodopyridine (850.0 mg, 3.32 mmol), zinc cyanide (234.8 mg, 2.0 mmol, 0.6 eq.), Pd(PPh3)4 (191.8 mg, 5 mol%) were placed in a sealed tube, protected with nitrogen, and then anhydrous NMP (3.0 mL) was added and reacted at 120° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 2-amino-4-chloro-3-cyanopyridine (432.2 mg, 85% yield). Step 2: Synthesis of compound 19-1 Compounds 2-amino-4-chloro-3-cyanopyridine (220.0 mg, 1.43 mmol), 5-chloro-2-mercaptopyrazine (252.2 mg, 1.72 mmol, 1.2 eq.), Pd2(dba)3 (26.2 mg, 2 mol%), Xantphos (49.6 mg, 6 mol%), and DIPEA (369.8 mg, 2.86 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (1.0 mL) was added and reacted at 95° C. overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 19-1 (171.3 mg, 45% yield). Step 3: Synthesis of compound 19-2 Compound 19-1 (107.0 mg, 0.41 mmol) and intermediate III-2 (123.5 mg, 0.45 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 19-2 (134.4 mg, 60% yield). Step 4: Synthesis of compound 19-3 Compound 19-2 (100.0 mg, 0.20 mmol), compound 11-5 (71.0 mg, 0.22 mmol, 1.1 eq.), Pd2(dba)3 (3.7 mg, 2 mol%), Xantphos (6.9 mg, 6 mol%), and cesium carbonate (130.3 mg, 0.40 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 95 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 19-3 (91.7 mg, 60% yield). Step 5: Synthesis of compound 19 Compound 19-3 (80.0 mg, 0.10 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 19 (8.9 mg, 13% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.50 (d, J = 3.6 Hz, 1H), 8.30 (d, J = 1.1 Hz, 1H), 8.27 (d, J = 5.5 Hz, 1H), 8.24 (d, J = 1.0 Hz, 1H), 8.21 (d, J = 1.2 Hz, 1H), 8.19 (s, 1H), 7.76 (d, J = 11.7 Hz, 1H), 6.55 (d, J = 5.5 Hz, 1H), 4.75 (p, J = 6.9 Hz, 1H), 4.26 - 4.15 (m, 1H), 4.09 - 3.93 (m, 2H), 3.85 (d, J = 8.8 Hz, 1H), 3.71 (d, J = 8.8 Hz, 1H), 3.59 - 3.36 (m, 2H), 3.04 (d, J = 4.5 Hz, 1H), 2.69 (s, 3H), 1.99 - 1.88 (m, 1H), 1.82 - 1.61 (m, 9H), 1.26 (d, J = 6.2 Hz, 3H).
[0060] (Example 20) [ka] Step 1: Synthesis of compound 20-1 Compounds 2-amino-5-chloro-6-bromopyridine (250.0 mg, 1.20 mmol), 5-chloro-2-mercaptopyrazine (211.1 mg, 1.44 mmol, 1.2 eq.), CuI (45.7 mg, 0.2 eq.), 1,10-phenanthroline (86.5 mg, 0.4 eq.), and K3PO4 (509.5 mg, 2.40 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (2.0 mL) was added and reacted overnight at 110° C. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 20-1 (127.7 mg, 39% yield). Step 2: Synthesis of compound 20-2 Compound 20-1 (102.0 mg, 0.37 mmol) and intermediate III-2 (112.5 mg, 0.41 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred at 95° C. overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 20-2 (43.2 mg, 23% yield). Step 3: Synthesis of compound 20-3 Compound 20-2 (43.2 mg, 0.085 mmol), compound 11-5 (30.3 mg, 0.094 mmol, 1.1 eq.), Pd2(dba)3 (1.6 mg, 2 mol%), Xantphos (3.0 mg, 6 mol%), and DIPEA (22.0 mg, 0.17 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 95 ° C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain crude compound 20-3 (22.3 mg). Step 4: Synthesis of compound 20 Compound 20-3 (22.3 mg, 0.028 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 20 (9.7 mg, 16% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.37 (d, J = 3.7 Hz, 1H), 8.29 (d, J = 1.3 Hz, 1H), 8.22 (d, J = 1.3 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.10 (d, J = 1.0 Hz, 1H), 7.76 - 7.67 (m, 2H), 7.54 (d, J = 8.7 Hz, 1H), 4.73 (p, J = 7.0 Hz, 1H), 4.27 - 4.16 (m, 1H), 4.07 - 3.90 (m, 2H), 3.84 (d, J = 8.8 Hz, 1H), 3.73 (d, J = 8.8 Hz, 1H), 3.58 - 3.36 (m, 2H), 3.03 (d, J = 4.6 Hz, 1H), 2.69 (s, 3H), 2.00 - 1.89 (m, 1H), 1.84 - 1.67 (m, 9H), 1.25 (d, J = 6.4 Hz, 3H).
[0061] Example 21 [ka] Step 1: Synthesis of compound 2-amino-4-chloro-5-iodopyridine Compound 2-amino-4-chloropyridine (1.00g, 7.78mmol), NIS (1.92g, 8.56mmol, 1.1eq.), and DMF (15.0ml) were placed in a 50ml one-neck flask and reacted at room temperature for 3h. After monitoring the complete reaction, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 2-amino-4-chloro-5-iodopyridine (1.10g, 56% yield). Step 2: Synthesis of compound 21-1 Compounds 2-amino-4-chloro-5-iodopyridine (250.0 mg, 1.0 mmol), 5-chloro-2-mercaptopyrazine (161.3 mg, 1.1 mmol, 1.1 eq.), CuI (38.1 mg, 0.2 eq.), 1,10-phenanthroline (72.1 mg, 0.4 eq.), and K3PO4 (424.6 mg, 2.00 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (2.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 21-1 (145.2 mg, 53% yield). Step 3: Synthesis of compound 21-2 Compound 21-1 (145.2 mg, 0.53 mmol) and intermediate III-2 (158.6 mg, 0.58 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 21-2 (115.0 mg, 23% yield). Step 4: Synthesis of compound 21-3 Compound 21-2 (115.0 mg, 0.22 mmol), compound 11-5 (77.5 mg, 0.24 mmol, 1.1 eq.), Pd2(dba)3 (4.0 mg, 2 mol%), Xantphos (7.6 mg, 6 mol%), and DIPEA (56.9 mg, 0.44 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 95 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 21-3 (91.5 mg, 52% yield). Step 5: Synthesis of compound 21 Compound 21-3 (75.0 mg, 0.094 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 21 (18.0 mg, 28% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.66 (s, 1H), 8.47 (d, J = 3.7 Hz, 1H), 8.39 (s, 1H), 8.38 (s, 1H), 8.15 (d, J = 1.3 Hz, 1H), 8.11 (d, J = 1.4 Hz, 1H), 8.05 (d, J = 1.4 Hz, 1H), 7.77 (d, J = 11.6 Hz, 1H), 4.76 (p, J = 6.9 Hz, 1H), 4.23 - 4.13 (m, 1H), 3.92 - 3.76 (m, 3H), 3.68 (d, J = 8.8 Hz, 1H), 3.46 - 3.24 (m, 2H), 2.98 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.91 - 1.80 (m, 1H), 1.75 - 1.61 (m, 9H), 1.23 (d, J = 6.4 Hz, 3H).
[0062] Example 22 [ka] Step 1: Synthesis of compound 22-1 Compound 2-amino-4-chloropyrimidine (500.0 mg, 3.9 mmol) and compound 5-chloro-2-mercaptopyrazine (628.9 mg, 4.29 mmol, 1.1 eq.) were dissolved in 10.0 ml of NMP, potassium carbonate (1.08 g, 7.80 mmol, 2 eq.) was added, and the mixture was stirred at room temperature overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to obtain compound 22-1 (304.1 mg, 33% yield). Step 2: Synthesis of compound 22-2 Compound 22-1 (120.0 mg, 0.50 mmol) and intermediate III-2 (175.6 mg, 0.64 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 22-2 (105.4 mg, 46% yield). Step 3: Synthesis of compound 22-3 Compound 22-2 (105.4 mg, 0.22 mmol), compound 11-5 (77.5 mg, 0.24 mmol, 1.1 eq.), Pd2(dba)3 (4.0 mg, 2 mol%), Xantphos (7.6 mg, 6 mol%), and DIPEA (56.9 mg, 0.44 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 95 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 22-3 (47.1 mg, 37% yield). Step 4: Synthesis of compound 22 Compound 22-3 (42.0 mg, 0.055 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 22 (23.0 mg, 63% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.52 (d, J = 3.5 Hz, 1H), 8.34 (d, J = 1.4 Hz, 1H), 8.31 (d, J = 5.5 Hz, 1H), 8.23 (d, J = 1.3 Hz, 1H), 8.21 (d, J = 1.4 Hz, 1H), 7.84 (d, J = 11.7 Hz, 1H), 6.60 (d, J = 5.5 Hz, 1H), 4.76 (p, J = 7.0 Hz, 1H), 4.26 - 4.16 (m, 1H), 4.07 - 3.92 (m, 2H), 3.85 (d, J = 9.0 Hz, 1H), 3.72 (d, J = 9.0 Hz, 1H), 3.56 - 3.34 (m, 2H), 3.05 (d, J = 4.6 Hz, 1H), 2.70 (s, 3H), 1.98 - 1.86 (m, 1H), 1.82 - 1.68 (m, 9H), 1.26 (d, J = 6.4 Hz, 3H).
[0063] Example 23 [ka] Step 1: Synthesis of compound 23-1 Compounds 3-chloro-4-iodoaniline (300.0 mg, 1.20 mmol), 5-chloro-2-mercaptopyrazine (193.5 mg, 1.32 mmol, 1.1 eq.), CuI (45.7 mg, 0.2 eq.), 1,10-phenanthroline (86.5 mg, 0.4 eq.), and K3PO4 (331.7 mg, 2.40 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, after which anhydrous dioxane (2.0 mL) was added and reacted at 110° C. overnight. After monitoring that the reaction was complete, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 23-1 (212.4 mg, 56% yield). Step 2: Synthesis of compound 23-2 Compound 23-1 (120.0 mg, 0.44 mmol) and intermediate III-2 (131.7 mg, 0.48 mmol, 1.1 eq.) were dissolved in 1.0 ml of NMP, DIPEA (1.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 23-2 (93.5 mg, 41% yield). Step 3: Synthesis of compound 23-3 Compound 23-2 (80.0 mg, 0.16 mmol), compound 11-5 (58.1 mg, 0.18 mmol, 1.1 eq.), Pd2(dba)3 (2.9 mg, 2 mol%), Xantphos (5.6 mg, 6 mol%), and DIPEA (41.4 mg, 0.32 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 95 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 23-3 (67.3 mg, 53% yield). Step 4: Synthesis of compound 23 Compound 23-3 (60.0 mg, 0.075 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the reaction was complete, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 23 (42.6 mg, 82% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.37 (d, J = 3.8 Hz, 1H), 8.15 (d, J = 1.2 Hz, 1H), 8.11 - 8.07 (m, 2H), 8.05 (d, J = 2.2 Hz, 1H), 7.76 (d, J = 11.6 Hz, 1H), 7.38 (dd, J = 8.6, 2.2 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.28 (s, 1H), 4.75 (p, J = 7.0 Hz, 1H), 4.23 - 4.14 (m, 1H), 3.94 - 3.76 (m, 3H), 3.68 (d, J = 8.8 Hz, 1H), 3.47 - 3.24 (m, 2H), 2.99 (d, J = 4.5 Hz, 1H), 2.70 (s, 3H), 1.92 - 1.80 (m, 1H), 1.76 - 1.67 (m, 9H), 1.23 (d, J = 6.4Hz, 3H).
[0064] (Example 24) [ka] Step 1: Synthesis of compound 24-1 Compound 9-3 (106.0 mg, 0.2 mmol), compound 11-5 (58.0 mg, 0.18 mmol, 0.9 eq.), Pd2(dba)3 (2.9 mg, 2 mol%), Xantphos (5.6 mg, 6 mol%), and cesium carbonate (41.4 mg, 0.32 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 105 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 24-1 (88.6 mg, 61% yield). Step 2: Synthesis of compound 24 Compound 24-1 (80.0 mg, 0.1 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 24 (38.0 mg, 54% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.48 (d, J = 3.7 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.31 (s, 1H), 8.18 (d, J = 1.2 Hz, 1H), 8.16 (d, J = 1.2 Hz, 1H), 8.12 (d, J = 1.1 Hz, 1H), 7.75 (d, J = 11.9 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.37 - 7.29 (m, 1H), 7.26 - 7.16 (m, 3H), 4.73 (p, J = 6.9 Hz, 1H), 4.25 - 4.11 (m, 2H), 3.99 (s, 1H), 3.31 - 3.15 (m, 2H), 3.09 (d, J = 15.6 Hz, 1H), 2.73 (d, J = 15.6 Hz, 1H), 2.70 (s, 3H), 1.93 - 1.75 (m, 2H), 1.70 (d, J = 7.0 Hz, 6H), 1.38 (d, J = 11.5 Hz, 2H).
[0065] (Example 25) [ka] Step 1: Synthesis of 3-(t-butylthio)-2-chloroaniline Compound 3-fluoro-2-chloroaniline (1.00 g, 6.87 mmol), t-butyl mercaptan (1.86 g, 20.61 mmol, 3.0 eq.), cesium carbonate (3.36 g, 10.31 mmol, 1.5 eq.), and DMSO (15.0 mL) were placed in a single-neck flask and reacted overnight under nitrogen protection at 120° C. After monitoring the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 3-(t-butylthio)-2-chloroaniline crude product (1.67 g). Step 2: Synthesis of 2-chloro-3-mercaptoaniline The compound 3-(t-butylthio)-2-chloroaniline (1.67 g, 7.74 mmol) was dissolved in 15.0 mL of concentrated hydrochloric acid and reacted overnight at 80° C. After monitoring that the reaction was complete, the solution was adjusted to alkaline with sodium carbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain the compound 2-chloro-3-mercaptoaniline (577.5 mg, total yield of 47% for the two steps). Step 3: Synthesis of 25-1 Compound 2-chloro-3-mercaptoaniline (577.5 mg, 3.62 mmol) and compound 2,5-dichloropyrazine (593.0 mg, 3.98 mmol, 1.1 eq.) were dissolved in 4.0 ml of NMP, potassium carbonate (1.00 g, 7.24 mmol, 2 eq.) was added, and the mixture was stirred at room temperature overnight. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to obtain compound 25-1 (112.5 mg, 11% yield). Step 4: Synthesis of 25-2 Compound 25-1 (71.5.0 mg, 0.26 mmol) and intermediate III-2 (85.1 mg, 0.31 mmol, 1.2 eq.) were dissolved in 1.0 ml of NMP, DIPEA (2.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 25-2 (71.7 mg, 54% yield). Step 5: Synthesis of 25-3 Compound 25-2 (71.7 mg, 0.14 mmol), compound 11-5 (35.5 mg, 0.11 mmol, 0.8 eq.), Pd2(dba)3 (5.1 mg, 4 mol%), Xantphos (9.8 mg, 12 mol%), and cesium carbonate (91.3 mg, 0.28 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 105 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 25-3 (50.0 mg, 46% yield). Step 6: Synthesis of compound 25 Compound 25-3 (45.0 mg, 0.058 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 25 (24.0 mg, 60% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.48 (dd, J = 8.4, 1.4 Hz, 1H), 8.39 (d, J = 3.8 Hz, 1H), 8.27 - 8.14 (m, 3H), 7.85 - 7.74 (m, 2H), 7.17 (t, J = 8.1 Hz, 1H), 6.73 (dd, J = 7.9, 1.4 Hz, 1H), 4.73 (p, J = 6.9 Hz, 1H), 4.26 - 4.14 (m, 1H), 4.00 - 3.85 (m, 2H), 3.82 (d, J = 8.8 Hz, 1H), 3.70 (d, J = 8.8 Hz, 1H), 3.53 - 3.28 (m, 2H), 3.00 (d, J = 4.5 Hz, 1H), 2.69 (s, 3H), 1.95 - 1.83 (m, 1H), 1.79 - 1.66 (m, 9H), 1.24 (d, J = 6.4 Hz, 3H).
[0066] (Example 26) [ka] Step 1: Synthesis of compound 26-1 Compound 2-amino-4-iodopyridine (250.0 mg, 1.14 mmol), 5-chloro-2-pyrazine sodium sulfide (249.5 mg, 1.48 mmol, 1.3 eq.), Pd2(dba)3 (21.1 mg, 2 mol%), Xantphos (19.7 mg, 3 mol%), DIPEA (294.1 mg, 2.28 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (3.0 mL) was added and reacted at 95 ° C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 26-1 (178.0 mg, 65% yield). Step 2: Synthesis of compound 26-2 Compound 26-1 (120.0 mg, 0.50 mmol) and intermediate III-2 (164.6 mg, 0.60 mmol, 1.2 eq.) were dissolved in 1.0 ml of NMP, DIPEA (2.5 mL) was added, and the mixture was stirred overnight at 95° C. After monitoring that the reaction was complete, the mixture was diluted with ethyl acetate, washed five times with saturated saline, and the organic phase was concentrated and separated by column chromatography to give compound 26-2 (142.2 mg, 60% yield). Step 3: Synthesis of compound 26-3 Compound 26-2 (130.0 mg, 0.27 mmol), compound 11-5 (74.2 mg, 0.23 mmol, 0.85 eq.), Pd2(dba)3 (10.1 mg, 4 mol%), Xantphos (18.5 mg, 12 mol%), and cesium carbonate (176.0 mg, 0.54 mmol, 2 eq.) were placed in a sealed tube and protected with nitrogen, and then anhydrous dioxane (1.0 mL) was added and reacted at 105 °C overnight. After monitoring that the reaction was complete, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to give compound 26-3 (110.0 mg, 53% yield). Step 4: Synthesis of compound 26 Compound 26-3 (90.0 mg, 0.12 mmol) was dissolved in EA (1.0 mL), EA·HCl (1.0 mL) was added, and the mixture was allowed to react at room temperature overnight. After monitoring the completion of the reaction, aqueous sodium carbonate was added to adjust the alkalinity, and the mixture was extracted with EA, dried, and concentrated to give compound 26 (65.0 mg, 82% yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.37 (d, J = 3.7 Hz, 1H), 8.35 (dd, J = 1.7, 0.7 Hz, 1H), 8.26 (d, J = 1.4 Hz, 1H), 8.21 - 8.04 (m, 3H), 8.01 (d, J = 1.4 Hz, 1H), 7.73 (d, J = 11.8 Hz, 1H), 6.62 (dd, J = 5.4, 1.7 Hz, 1H), 4.77 (p, J = 6.9 Hz, 1H), 4.20 (dd, J = 6.5, 4.6 Hz, 1H), 3.97 - 3.78 (m, 3H), 3.69 (d, J = 8.8 Hz, 1H), 3.50 - 3.27 (m, 2H), 3.01 (d, J = 4.6 Hz, 1H), 2.70 (s, 3H), 1.94 - 1.82 (m, 1H), 1.78 - 1.64 (m, 9H), 1.25 (d, J = 6.4 Hz, 3H). Testing SHP2 enzyme level activity in vitro
[0067] The activity of the compounds in the above examples at the SHP2 enzyme level is tested by the following procedure.
[0068] 4.1 Preparation of compounds The compounds were dissolved in 100% DMSO to prepare 30 mM stock solutions, which were then stored in a refrigerator at -20°C away from light.
[0069] 4.2 SHP2 reaction process (1) Prepare 1× Reaction Buffer. (2) Preparation of compound concentration gradient: The starting concentration of the test compound was 30 μM, and it was diluted 3-fold to 10 concentrations, and tested in a single well. The compound was diluted in a 384 source plate to a 100% DMSO solution at 100 times the final concentration, and the compound was diluted 3-fold to 10 concentrations using Precision. Using the dispenser Echo550, 250 nL of the compound at 100 times the final concentration was transferred to the target plate, the 384 plate. 250 nL of DMSO was added to the positive control, and 250 nL of 1 mM SHP099 was added to the negative control. (3) An activated peptide solution was prepared at 5 times the final concentration using 1× Reaction Buffer, and 5 μL of the solution was added to each reaction plate and centrifuged at 1,000 rpm for 1 minute. (4) An enzyme solution was prepared at 2.5 times the final concentration using 1× Reaction Buffer, and 10 μL of the solution was added to each reaction plate. The plate was centrifuged at 1,000 rpm for 1 minute and incubated at room temperature for 60 minutes. (5) A substrate solution was prepared at 2.5 times the final concentration using 1× Reaction Buffer, and 10 μL of the solution was added to each reaction plate. The plate was centrifuged at 1,000 rpm for 1 minute and incubated at room temperature for 20 minutes. (6) Ex355 / Em460 fluorescence values were read using EnSight.
[0070] 4.3 Data Analysis calculation formula
number
[0071] Testing CDK4 enzyme level activity in vitro
[0072] 5.1 Preparation of compounds The compounds were dissolved in 100% DMSO to prepare 30 mM stock solutions, which were then stored in a refrigerator at -20°C away from light.
[0073] 5.2 Kinase reaction process (1) 1× Kinase buffer was prepared. (2) Preparation of compound concentration gradient: The test concentration of the test compound was prepared according to the user's request from 30000nM, diluted in a 384 source plate to make a 100% DMSO solution at 100 times the final concentration, and the compound was diluted 3 times to a concentration of 10. Using the dispenser Echo550, 250nL of the compound at 100 times the final concentration was transferred to the target plate, a 384 well plate. (3) A kinase solution was prepared at 2.5 times the final concentration using 1× Kinase buffer. (4) 10 μL of kinase solution at 2.5 times the final concentration was added to the compound wells and the positive control wells, respectively. 10 μL of 1× Kinase buffer was added to the negative control wells. (5) After centrifugation at 1000 rpm for 30 seconds, the reaction plate was shaken to mix and incubated at room temperature for 10 minutes. (6) Using 1× Kinase buffer, a mixed solution of ATP and Kinase Substrate 8 was prepared at a final concentration of 25 / 15 times. (7) The reaction was started by adding 15 μL of a mixed solution of ATP and substrate at 5 / 3 times the final concentration. (8) The 384-well plate was centrifuged at 1000 rpm for 30 seconds, shaken to mix, and incubated at room temperature for 180 minutes. (9) The kinase reaction was stopped by adding 30 μL of stop detection solution, centrifuged at 1000 rpm for 30 seconds, and shaken to mix. (10) The conversion rate was read using a Caliper EZReader II.
[0074] 5.3 Data Analysis calculation formula
number
[0075] Specific results are shown in the table. [Table 2]
[0076] In vitro antiproliferative activity of compounds
[0077] 1. Experimental Steps (1) The PBS solution was autoclaved and stored in a refrigerator at 4°C. (2) Trypsin and pancreatin digestion solution were weighed, completely dissolved in ultrapure water, filtered through a micropore filter, and stored in a refrigerator at -20°C. (3) Weigh out the medium powder and NaHCO3, add ultrapure water to completely dissolve, add 10% diabody, filter through a microporous membrane to obtain culture solution, store in a refrigerator at 4°C, and add 10% fetal bovine serum before use. (4) MDA-MB-231, MDA-MB-468, or EMT6 cells were removed from the liquid nitrogen tank and immediately placed in a 37°C constant temperature water bath. After shaking to dissolve the cells, the cells were poured into a culture bottle and diluted by adding culture medium (containing 10% fetal bovine serum). The diluted medium was transferred to a centrifuge tube and centrifuged at 1000r / min for 5 minutes, the supernatant was discarded, new medium was added and mixed uniformly with a pipette, transferred to a culture bottle, and cultured in a 5% CO2, 37°C incubator. When the cells adhered and almost covered the bottom of the bottle, subculture was started, a small amount of new medium (containing 10% fetal bovine serum) was added to stop digestion, the liquid in the culture bottle was discarded, washed twice with PBS, new medium was added and mixed uniformly with a pipette, and the culture was continued by dividing it evenly into two culture bottles. (5) The cells in the logarithmic phase were removed, the old medium was discarded, and trypsin solution was added to digest for 3 minutes, after which new medium containing 10% fetal bovine serum was added to stop the digestion, the solution was transferred to a centrifuge tube, centrifuged at 1000r / min for 5 minutes, and the supernatant was discarded. Culture medium was added to prepare a cell suspension, and cell counting was performed. After counting was completed, the cells were seeded into a 96-well plate at a concentration of 5,000 to 10,000 cells per well. The 96-well plate containing the cells was placed in a 37°C, 5% CO2 incubator and cultured for 24 hours. The drugs were serially diluted to 90 μmol / L, 30 μmol / L, 10 μmol / L, 3.3 μmol / L, 1.1 μmol / L, and 0.37 μmol / L using culture medium, and then 100 μL of them were added per well to the 96-well plate, and three duplicate wells were set up for each concentration. For the control group, medium containing the corresponding concentration of solvent was added, and the same volume of blank medium was added to the zero well, and the wells were incubated in a 5% CO2, 37°C incubator for 3 days, with the medium replaced once every 2 days. 20 μL of MTT (5 mg / mL) was added to each well, mixed evenly, and incubated in a 5% CO2, 37°C incubator for 4 hours away from light. The liquid was removed from the 96-well plate, and 150 μL of LDMSO was added to each well and shaken with a microoscillator to completely dissolve the crystals at the bottom. The 96-well plate was then placed in a microplate reader for detection, and the absorbance at 490 nm was measured. Draw the curve and calculate the inhibition rate and IC of the drug on the cells. 50 was calculated. Inhibition rate = [(mean OD value of the control group - mean OD value of the experimental group) / (mean OD value of the control group - mean OD value of the blank control group)] × 100%.
[0078] 3. Experimental Results The inhibitory activities of the compounds against MDA-MB-231, MDA-MB-468, and EMT6 cell lines are as follows. [Table 3]
[0079] Experimental Conclusion: Compared with SHP2 inhibitors and CDK4 / 6 inhibitors administered alone or in combination, the compounds of several embodiments of the present invention have superior anti-proliferative effects on MDA-MB-231, MDA-MB-468 and EMT6 cells. Compound cell cycle experiments
[0080] MDA-MB-231 and MDA-MB-468 cell lines were seeded in 6-well plates and treated with DMSO, TNO155, abemaciclib, TNO155 + abemaciclib, or different concentrations of compound 12 for 48 h. Cells were washed once with PBS and 1 mL trypsin (0.25%) without EDTA was added. When cells were rounded and partially floating, PBS was added to stop the digestion. Cells were then collected and fixed in 70% ethanol (500 μL) for 24 h at 4 °C. Cells were collected by washing with PBS, centrifuged at 1500 rpm for 5 min, and stained with PI / RNase for 30–60 min at room temperature in the dark. After incubation, cells were analyzed by flow cytometry. All experiments were performed in triplicate.
[0081] Experimental Conclusion: As shown in Figures 1 and 2, compared with SHP2 inhibitors and CDK4 / 6 inhibitors administered alone or in combination, the compounds of several embodiments of the present invention have better G0 / G1 cycle arresting effects on MDA-MB-231 cells and MDA-MB-468 / G1 cells.
Claims
1. Compounds of general formula I, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. 【Chemical Formula 38】 (Ring A is C 3 ~C 6 Cycloalkyl, C 6 ~C 10 aromatic ring, C 6 ~C 10 cycloalkyl, aromatic, heteroaromatic, heterocyclic, spiro, bridged, and fused rings, wherein the cycloalkyl, aromatic, heteroaromatic, heterocyclic, spiro, bridged, and fused rings are selected from N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said cycloalkyl, aromatic ring, heteroaromatic ring, carbocycle, monoheterocycle, spirocycle, bridged ring, fused ring may optionally be substituted by one or more substituents; Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1 and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 1 is a chemical bond, NR a , C 1 ~C 2 Carbon chain, O, S(O) m where m is selected from 0, 1, and 2; L 2 is a chemical bond, NR a , C 1 ~C 2 Carbon chain, O, S(O) m where m is selected from 0, 1, and 2; Y 1 is N or CR 3 where R 3 is a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 1 ~C 6 Alkoxy, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl or C 3 ~C 6 cycloalkyl; Y 2 is N or CR 4 where R 4 is a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 1 ~C 6 Alkoxy, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl or C 3 ~C 6 cycloalkyl; R 1 and R 2 respectively represent hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atoms to which they are attached form a 3- to 12-membered monoheterocycle or polyheterocycle, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: 【Chemical Formula 39】 where W is absent or CR 6 R 7 , O., N.R. b , S(O) m where m is selected from 0, 1, and 2; Ring C is absent or 3 ~C 7 1-membered monocyclic ring or C 5 ~C 12 is selected from polycyclic rings, R a and R b are each independently a hydrogen atom, a deuterium atom, or C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl; R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C together with the carbon atom to which they are attached. 3 ~C 12 1-membered heterocycle or C 3 ~C 8 Forms a cycloalkyl.
2. Compounds of general formula II, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs, or prodrugs thereof: 【Chemistry 40】 (Ring A is C 3 ~C 6 Cycloalkyl, C 6 ~C 10 aromatic ring, C 6 ~C 10 cycloalkyl, aromatic, heteroaromatic, heterocyclic, spiro, bridged, and fused rings, wherein the cycloalkyl, aromatic, heteroaromatic, heterocyclic, spiro, bridged, and fused rings are selected from N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said cycloalkyl, aromatic ring, heteroaromatic ring, carbocycle, monoheterocycle, spirocycle, bridged ring, fused ring may optionally be substituted by one or more substituents; Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1 and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 1 is a chemical bond, NR a , C 1 ~C 2 Carbon chain, O, S(O) m where m is selected from 0, 1, and 2; L 2 is a chemical bond, NR a , C 1 ~C 2 Carbon chain, O, S(O) m where m is selected from 0, 1, and 2; R 1 and R 2 respectively represent hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C 1 ~C 6 is alkyl, Or, R 1 and R 2 together with the carbon atoms to which they are attached form a 3- to 12-membered monoheterocycle or polyheterocycle, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: 【Chemistry 41】 where W is absent or CR 6 R 7 , O., N.R. b , S(O) m where m is selected from 0, 1, and 2; Ring C is absent or 3 ~C 7 1-membered monocyclic ring or C 5 ~C 12 is selected from polycyclic rings, R a and R b are each independently a hydrogen atom, a deuterium atom, or C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl; R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C together with the carbon atom to which they are attached. 3 ~C 12 1-membered heterocycle or C 3 ~C 8 Forms a cycloalkyl.
3. Compounds of general formula III, and pharma- ceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof: embedded image 【Chemistry 42】 (A ring is hydrogen, 【Chemistry 43】 is selected from Ring B is selected from an aromatic ring, a heteroaromatic ring, a carbocyclic ring, and a heterocyclic ring, wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, and the heterocyclic ring are selected from N, O, and S(O) m wherein m is selected from 0, 1 and 2, and wherein said aromatic, heteroaromatic, carbocyclic, and heterocyclic rings may optionally be substituted by one or more substituents; L 2 is a chemical bond, NR a , C 1 ~C 2 Carbon chain, O, S(O) m where m is selected from 0, 1, and 2; R 1 and R 2 respectively represent hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxy, sulfonic acid group, C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atoms to which they are attached form a 3- to 12-membered monoheterocycle or polyheterocycle, wherein the monoheterocycle or polyheterocycle is selected from the group consisting of N, O, and S(O) m where m is selected from 0, 1 and 2, and wherein said mono- or polyheterocycle may be unsubstituted or substituted by one or more substituents; Or, R 1 and R 2 together with the carbon atom to which they are attached form: 【Chemistry 44】 where W is absent or CR 6 R 7 , O., N.R. b , S(O) m where m is selected from 0, 1, and 2; Ring C is absent or 3 ~C 7 1-membered monocyclic ring or C 5 ~C 12 is selected from polycyclic rings, R a and R b are each independently a hydrogen atom, a deuterium atom, or C 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl; R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a deuterium atom, a halogen atom, an amino group, a hydroxyl group, a cyano group, a nitro group, a carboxyl group, a sulfonic acid group, 1 ~C 6 Alkyl, C 3 ~C 6 Cycloalkyl, C 6 ~C 10 Aryl, C 6 ~C 10 heteroaryl, wherein said amino, hydroxy, aryl, heteroaryl, cycloalkyl may be optionally substituted by one or more substituents; Or, R 4 and R 5 are CO, C=NH, C together with the carbon atom to which they are attached. 3 ~C 12 1-membered heterocycle or C 3 ~C 8 Forms a cycloalkyl.
4. 4. The compound according to claim 3, characterized in that it has any of the following structural formulas: 【Table 4】
5. A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 and a pharma- ceutically acceptable excipient.
6. 6. The pharmaceutical composition according to claim 5, which is prepared into a tablet, capsule, injection solution, or freeze-dried powder.
7. Use of a compound according to claims 1 to 3, a pharmaceutical composition according to claim 5 or 6 in the preparation of an antitumor drug, a prodrug as an antitumor drug or an intermediate as an antitumor drug.
Citation Information
Patent Citations
Novel heterocyclic derivative capable of being used as SHP2 inhibitor
CN110143949A
Compounds and compositions for inhibiting the activity of shp2
JP2018517752A
Pyrimidine or pyridopyrodon compounds, and their applications
JP2018534352A
CDK4 / 6 inhibitors
JP2020510083A
Novel heterocyclic derivatives useful as SHP2 inhibitors
JP2020515538A
